A Phase II, Open-Label Exploratory Study Investigating the Efficacy of Toviaz for Treatment of Adult Patients With Spinal Cord Injury With Neurogenic Detrusor Overactivity for Amelioration of Autonomic Dysreflexia(PIIR-AK-TOVIAZ-AD)
Latest Information Update: 14 Dec 2022
Price :
$35 *
At a glance
- Drugs Fesoterodine (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 05 Sep 2019 Status changed from recruiting to completed.
- 31 Aug 2018 Results presented at the 48th Annual Meeting of the International Continence Society
- 30 Apr 2018 Planned End Date changed from 1 Oct 2017 to 31 Dec 2018.